**Organization Overview:**
Adaptive Biotechnologies empowers revolutionary insights into the adaptive immune system that will change the course of medicine by combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors.

Adaptive brings the accuracy and sensitivity of its immunosequencing platform into laboratories around the world to drive groundbreaking research. The Company is also committed to translating its immunosequencing discoveries into clinical diagnostics and therapeutics to improve patient care in cancer and other immune-mediated diseases.

Adaptive is committed to transforming the diagnosis and treatment of immune-mediated diseases including cancer, autoimmune disorders, and infectious disease through ground-breaking immunosequencing applications.

- **Adaptive Biotechnologies illuminates the adaptive immune system** through high-throughput bias-controlled sequencing of T- and B-cell receptors, and makes this sequencing data accessible through a proprietary data analysis and visualization platform.

- **With constant dedication to discovery and ever-evolving product development**, Adaptive empowers researchers and clinicians to discover the brilliance of the adaptive immune system.

- Adaptive Biotechnologies is on the forefront of creating and enabling revolutionary immune-based discoveries that will radically advance science and medicine worldwide.

**Management Team:**

**Chad Robins**, President, Chief Executive Officer and Co-Founder

**Harlan Robins**, Chief Scientific Officer and Co-Founder

**Melina Cimler**, SVP, Regulatory and Quality

**Kathleen Determann**, General Counsel

**Malek Faham**, SVP, Innovation

**Brian Hansen**, Chief Commercial Officer

**Nancy Hill**, SVP and GM, Research Products

**Sean Nolan**, Chief Technical Officer

**Julie Rubinstein**, EVP, Corporate and Business Development

**Dean Schorno**, Chief Financial Officer

**Erin Shackelford**, VP, Human Resources

**Tom Willis**, SVP and GM, Diagnostic Products
Research/Product Focus:

immunoSEQ® PLATFORM
Adaptive helps researchers make discoveries in oncology, autoimmune disorders and infectious diseases by offering fee-for-service access to its proprietary immune profiling sequencing technology under the immunoSEQ brand name. The immunoSEQ Kit for research use only is now available to facilitate the integration of immunosequencing into research centers. The immunoSEQ Assay is not for use in diagnostic procedures.

clonoSEQ® PROCESS
Adaptive’s clonoSEQ Process enables physicians to utilize sequencing-based minimal residual disease (MRD) detection as an aid to clinical decision making for patients with lymphoid cancers (blood cancers). With its ability to detect cancer cells at a level as low as one per one million white blood cells, the clonoSEQ MRD Test is one to two orders of magnitude more sensitive than the other methods of MRD detection, such as ASO-PCR and flow cytometry. The clonoSEQ Process was previously marketed as the ClonoSIGHT™ process by Sequenta, Inc., which was acquired by Adaptive Biotechnologies in January 2015.

The company is also validating a second novel oncology diagnostic to quantify the presence and clonality of Tumor Infiltrating Lymphocytes (“TILs”) and to create a reliable measure of “immunocompetency” to predict or monitor response to cancer treatments that directly alter the host immune system.

Recent Milestones:
immunoSEQ Kit Launch – Q4, 2014
Sequenta Acquisition – Q1, 2015
Series F Financing Closure, $195MM – Q2, 2015

Intellectual Property Status:
Privately Held
Public Relations and Newsworthy Events:

- Adaptive Biotechnologies to Present Data from Largest Study to Date Demonstrating Superior Sensitivity and Prognostic Value of Next-Generation Sequencing-Based Minimal Residual Disease (MRD) Detection in Pediatric Acute Lymphoblastic Leukemia
- Children’s Oncology Group/Pediatric Blood and Marrow Transplant Consortium Study Shows Adaptive Biotechnologies’ clonoSEQ® Minimal Residual Disease (MRD) Test Superior to Flow Cytometry in Predicting Post-Transplant Relapse and Survival in ALL
- Adaptive Biotechnologies and Collaborators to Present Eight Studies at the 2015 American Society of Clinical Oncology Annual Meeting Demonstrating the Relevance of Monitoring Immune Receptors as a New Class of Biomarkers
- Adaptive Biotechnologies’ immunoSEQ® Assay Provides Groundbreaking Insight into T-Cell Fate, Significantly Advancing Understanding of Adaptive Immunity
- Adaptive Biotechnologies and Collaborators to Present 5 Studies Demonstrating Utility of Immunosequencing to Determine T-cell Function in Chronic and Infectious Diseases at the 2015 American Association of Immunologists Annual Meeting
- Adaptive Biotechnologies Enhances Leading Position in Growing Immunosequencing Market with Completion of $195 Million Investment
- Adaptive Biotechnologies and Researchers from MD Anderson Cancer Center Demonstrate Ability to Detect Hodgkin’s Lymphoma in Blood
- Adaptive Biotechnologies’ clonoSEQ Minimal Residual Disease Test Detects Relapse with Higher Specificity than PET/CT in Diffuse Large B-Cell Lymphoma Patients
- Adaptive Biotechnologies and Collaborators to Present 4 Studies Demonstrating Clinical Relevance of Immunosequencing in the Treatment of Solid Tumors at the 2015 American Association for Cancer Research Annual Meeting
- Multiple Myeloma Research Foundation, University of Torino and Adaptive Biotechnologies Work to Speed Novel Minimal Residual Disease Monitoring Technologies to Patients
- Adaptive Biotechnologies’ clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA
- Adaptive Management Team Members to Present at Upcoming Conferences
- Adaptive Biotechnologies adds Chad Cohen, Zillow Group CFO, to Board of Directors
- Adaptive Biotechnologies Announces Acquisition of Sequenta, Inc.

Goals for presentation:
Community Exposure
Investment
Strategic Partnerships
Collaboration